| Bioactivity | MPT0B002 is a potent microtubule inhibitor with anticancer activities. MPT0B002 disrupts tubulin polymerization, induces apoptosis, and arrests cell cycle at the G2/M phase[1]. |
| Invitro | MPT0B002 (1-1000 nM；48 小时) 可诱导 G2/M 期细胞周期停滞[1]。MPT0B002 (100 nM；24 小时) 以剂量依赖性方式抑制 K562、BaF3/p210 和 BaF3/T315I 细胞中的细胞活力[1]。 MPT0B002 (100 nM; 48 h) 诱导细胞凋亡，并可下调 Bcr-Abl 和 Bcr-Abl-T315I mRNA 表达和蛋白质水平以及下游信号通路[1]。K562, BaF3/p210, and BaF3/T315I cells100 nM24 hInduced G2/M-phase cell cycle arrest.K562, BaF3/p210, and BaF3/T315I cells100 nM48 hInduced apoptosis and caspase-3 pathway.K562, BaF3/p210, and BaF3/T315I cells100 nM48 hSignificantly reduced the expression level of Bcr-Abl, and reduced the phosphorylations of Crkl and Stat5. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MPT0B002 相关抗体: Cell Viability Assay[1] Cell Line: |
| CAS | 946077-08-3 |
| Formula | C19H19NO4 |
| Molar Mass | 325.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yi-Yen Yeh, et al. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Invest New Drugs. 2017 Aug;35(4):427-435. |